The role of absorption studies in humans is to be examined by one of the pharmaceutical industry's leading authorities in oral drug delivery in a web-based seminar
The role of absorption studies in humans is to be examined by one of the pharmaceutical industry's leading authorities in oral drug delivery in the first in a series of webinars (web-based seminars).
The on-line sessions have been designed by Pharmaceutical Profiles to address some of the key challenges facing all companies developing pharmaceutical products.
The first webinar on 4 June 2003 at 4.00pm UK/5.00pm central Europe/11.00am eastern USA/8.00am Pacific USA will be delivered by Professor Ian Wilding - a frequent speaker at international meetings and a respected authority on drug delivery and intestinal absorption.
In 1997, he served as an expert scientist for the FDA in the area of Food Effects on Drug Bioavailability and is currently the only European scientist working with PQRI (an FDA/AAPS initiative) examining US regulatory guidance in the area of oral biopharmaceutics.
He is also on the advisory board for the University of Nottingham Institute of Enterprise and Innovation and is a member of the steering committee for the East Midlands MediLink programme, designed to improve connectivity between universities, hospitals, SMEs and large companies within the healthcare discipline in the region.
Professor Wilding explained; "Pharmacokinetic (PK) or bioavailability issues have to be taken into account when drugs are selected as full development candidates.
However, the difficulty still exists to screen for human PK properties.
"The correlation between pre-clinical animal models and man is far from convincing. However, one of the main reasons for the prediction dilemma has been the limited understanding of what controls human drug absorption.
New techniques for assessing which factors influence oral drug absorption in different regions of the gastrointestinal tract have gone some way in addressing this.
"Pharmaceutical and drug delivery companies are undertaking human drug absorption studies to create more reliable 'route maps' for developing new drugs with complex PK properties.
Such studies are ideal for generating radical innovations in development by providing mechanisms to make informed decisions about the likely chance of bioavailability success for a candidate drug through optimised formulation development.
That is the process this webinar will examine." Anyone wishing to participate in the webinar can register through the Pharmaceutical Profiles website following the link to 'news'.
